Literature DB >> 18535394

Historical and clinical perspectives of the expanded disability status scale.

John F Kurtzke1.   

Abstract

BACKGROUND: The measurement of neurologic impairment in multiple sclerosis (MS) is of importance in treatment trials and course of illness.
METHODS: This review describes the rationale underlying the formation and use of a bifid rating system, the (Expanded) Disability Status Scale (DSS) and the Functional Systems (FS).
RESULTS: All signs found at neurologic examination in MS can be consolidated into 8 mutually exclusive FS: pyramidal, cerebellar, brain stem, sensory, bowel and bladder, visual, cerebral and other, each of which, save 'other', is given ordinal grades from 0 to 5 or 6. Each FS correlates with the DSS, a step scale from 0 (normal) to 10 (death due to MS), which is an overall measure of neurologic abnormality. Dividing steps 1-9 each into 2 gives the Expanded DSS. The FS and DSS were used in an Army series to describe neurologic status at first diagnosis and over the first 20 years of illness. DSS severity at 5 years after onset, but not earlier, was highly predictive of later severity.
CONCLUSIONS: Combination of the (Expanded) DSS and FS has been used successfully to assess impairment for natural history and treatment studies in MS. (c) 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2008        PMID: 18535394     DOI: 10.1159/000136645

Source DB:  PubMed          Journal:  Neuroepidemiology        ISSN: 0251-5350            Impact factor:   3.282


  29 in total

1.  Sativex(®) and clinical-neurophysiological measures of spasticity in progressive multiple sclerosis.

Authors:  Letizia Leocani; Arturo Nuara; Elise Houdayer; Irene Schiavetti; Ubaldo Del Carro; Stefano Amadio; Laura Straffi; Paolo Rossi; Vittorio Martinelli; Carlos Vila; Maria Pia Sormani; Giancarlo Comi
Journal:  J Neurol       Date:  2015-08-20       Impact factor: 4.849

2.  Use of herbal remedies by multiple sclerosis patients: a nation-wide survey in Italy.

Authors:  A Loraschi; P Bellantonio; F Bortolon; R Capra; P Cavalla; G Costantino; A Lugaresi; V Martinelli; M G Marrosu; F Patti; M Rottoli; M Salvetti; P Sola; C Solaro; C Klersy; F Marino; M Zaffaroni; M Cosentino
Journal:  Neurol Sci       Date:  2016-02-19       Impact factor: 3.307

3.  Comparison of Visual Field Parameters in Early and Advanced Stages of Multiple Sclerosis Patients Without a History of Optic Neuritis.

Authors:  Mete Güler; Peykan Türkçüoğlu; Turgut Yılmaz; Tahir Kurtuluş Yoldaş; Roomasa Channa
Journal:  Neuroophthalmology       Date:  2013-03-22

4.  Endovascular correction of cerebrovenous anomalies in multiple sclerosis: a retrospective review of an uncontrolled case series.

Authors:  Michael D Dake; Nicholas Dantzker; William L Bennett; John P Cooke
Journal:  Vasc Med       Date:  2012-04-10       Impact factor: 3.239

5.  Unmet needs of patients feeling severely affected by multiple sclerosis in Germany: a qualitative study.

Authors:  Maren Galushko; Heidrun Golla; Julia Strupp; Ute Karbach; Claudia Kaiser; Nicole Ernstmann; Holger Pfaff; Christoph Ostgathe; Raymond Voltz
Journal:  J Palliat Med       Date:  2014-02-14       Impact factor: 2.947

6.  Longitudinal changes of cerebral glutathione (GSH) levels associated with the clinical course of disease progression in patients with secondary progressive multiple sclerosis.

Authors:  In-Young Choi; Phil Lee; Abbey J Hughes; Douglas R Denney; Sharon G Lynch
Journal:  Mult Scler       Date:  2016-09-12       Impact factor: 6.312

7.  Walking impairment in patients with multiple sclerosis: exercise training as a treatment option.

Authors:  Robert W Motl; Myla D Goldman; Ralph H B Benedict
Journal:  Neuropsychiatr Dis Treat       Date:  2010-11-16       Impact factor: 2.570

8.  THC/CBD oromucosal spray in patients with multiple sclerosis overactive bladder: a pilot prospective study.

Authors:  Giorgia Teresa Maniscalco; R Aponte; D Bruzzese; G Guarcello; V Manzo; M Napolitano; O Moreggia; F Chiariello; C Florio
Journal:  Neurol Sci       Date:  2017-10-19       Impact factor: 3.307

9.  Deep gray matter T2 hypointensity correlates with disability in a murine model of MS.

Authors:  Istvan Pirko; Aaron J Johnson; Anne K Lohrey; Yi Chen; Jun Ying
Journal:  J Neurol Sci       Date:  2009-01-21       Impact factor: 3.181

10.  Consistent induction of chronic experimental autoimmune encephalomyelitis in C57BL/6 mice for the longitudinal study of pathology and repair.

Authors:  Jonathan P C Hasselmann; Hawra Karim; Anna J Khalaj; Subir Ghosh; Seema K Tiwari-Woodruff
Journal:  J Neurosci Methods       Date:  2017-04-08       Impact factor: 2.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.